Brief Title
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Official Title
A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies
Brief Summary
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and
AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of
patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as
well as a variety of other tumor types.
This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy
or combination therapy in patients with advanced and recurrent malignancies to establish a
recommended Phase 2 dose (RP2D) for future studies.
Patients are currently being recruited for Part 3 of the study.
Critical Outcome Technologies Inc. has been renamed to Cotinga Pharmaceuticals.
Detailed Description
This is a three-part, multi-center, open-label, Phase 1, first-in-patient study of COTI-2 in
patients with recurrent ovarian, fallopian tube, primary peritoneal, endometrial, or cervical
cancer (collectively gynecological malignancies), and in patients with head and neck squamous
cell carcinoma (HNSCC), colorectal, lung, or pancreatic cancer. Other tumor types may be
allowed with Sponsor approval.
COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by
2 treatment-free days each week.
Part 1 of the study will be dose finding in patients with gynecological malignancies using a
3 + 3 design to establish the MTD (maximum tolerated dose) over 6 planned cohorts.
Part 2 of the study will be dose finding in patients with HNSCC using a 3 + 3 design to
establish the MTD over 6 planned cohorts.
Part 3 of the study will be dose finding for COTI-2 in combination with cisplatin in patients
with gynecological malignancies, HNSCC, colorectal, lung, pancreatic cancer, or other tumor
types with Sponsor approval.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
Number of dose limiting Toxicities
Secondary Outcome
Clinical response
Condition
Ovarian Cancer
Intervention
COTI2
Study Arms / Comparison Groups
COTI2
Description: COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
51
Start Date
December 2015
Completion Date
June 2020
Primary Completion Date
December 2019
Eligibility Criteria
Inclusion Criteria
1. ≥18 years of age.
2. Willing and able to provide written informed consent to participate in this
investigational study.
3. Cancer that is recurrent, metastatic, or unresectable and for which no effective or
curative measures exist.
- Part 1: Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical
cancer
- Part 2: HNSCC, with confirmed p53 mutations
- Part 3: Gynecological malignancies, HNSCC, colorectal, lung, pancreatic cancer,
or other tumors with Sponsor approval.
4. Ability to attend all scheduled study visits
5. Measurable disease by physical examination or imaging as defined by RECIST v1.1
criteria or evaluable disease as defined by Gynecologic Cancer Intergroup (GCIG) CA125
criteria.
6. European Cooperative Oncology Group (ECOG) performance status 0 or 1.
7. Life expectancy ≥3 months.
8. Adequate bone marrow, liver, renal, and cardiac function at study entry, assessed as
follows:
- Hemoglobin ≥9.0 g/dL;
- Absolute neutrophil count (ANC) ≥1.5 x 109/L;
- Platelet count ≥100 x 109/L;
- Prothrombin time (PT) or international normalize rate (INR) within 1.5x upper
limit of normal;
- Partial thromboplastin time (PTT) within 1.5x upper limit of normal;
- Total bilirubin within normal limits;
- Alanine transaminase (ALT) and aspartate transaminase (AST) within 1.5x upper
limit of normal;
- Calculated creatinine clearance >50 mL/min;
- Urine protein <500 mg or urine protein: creatinine ratio (UPC) <1.0; and
- Left ventricular ejection fraction (LVEF) ≥55% (or the institutional lower limit
of normal [LLN]) as evidenced on ECHO.
9. Prior chemotherapy, other investigational agents, or radiation must be discontinued
for at least 28 days prior to the first administration of COTI-2. Hormone treatments
must be discontinued for at least 28 days prior to the first administration of COTI-2.
10. Toxicity from prior therapy (except alopecia) has resolved to ≤Grade 1; in the event
of toxicity that has not resolved to ≤Grade 1 but is considered stable, the patient
may be eligible after discussion among the investigator and sponsor's medical monitor.
11. Physiologically incapable of becoming pregnant, postmenopausal, or negative pregnancy
test and agree to use adequate contraception (e.g., oral contraceptive, double barrier
method, intra-uterine device, intra-muscular contraceptive).
12. Patients enrolled in the expansion phase must be willing to undergo pre and post-Cycle
1 biopsies.
13. Patients enrolled in the escalation and expansion phases will be required to have
archival tissue available for analysis.
Exclusion Criteria:
1. Pregnant or lactating.
2. History of other invasive malignancies, with the exception of non-melanoma skin cancer
or successfully treated in situ carcinoma, if there is evidence of the malignancy
being present within the last 3 years.
3. Inability to tolerate oral medications.
4. Any serious and/or unstable pre-existing medical, psychiatric, or other condition
(e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or
cardiac conditions which makes it undesirable for the patient to participate in the
study or which could jeopardize compliance with the protocol.
5. History of clinically significant or uncontrolled cardiac disease including but not
limited to:
1. Myocardial infarction,
2. Angina pectoris,
3. Congestive heart failure of New York Heart Association (NYHA) Grade >2,
4. Ventricular arrhythmias requiring continuous therapy, or
5. Supraventricular arrhythmias including atrial fibrillation, which are
uncontrolled.
6. Major surgery, excluding skin biopsies and procedures for insertion of central venous
access devices, within 28 days prior to the start of COTI-2.
7. Active, uncontrolled bacterial, viral, fungal, or other opportunistic infection
requiring systemic therapy.
8. Part 2:
1. The presence of or imminent occurrence of airway obstruction, unless tracheostomy
in place.
2. HPV-positive status ( In HNSCC patients only)
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Shannon Westin, MD, , [email protected]
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02433626
Organization ID
COTI2-101
Responsible Party
Sponsor
Study Sponsor
Critical Outcome Technologies Inc.
Collaborators
M.D. Anderson Cancer Center
Study Sponsor
Shannon Westin, MD, Principal Investigator, MD Anderson
Verification Date
January 2019